Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Off-Label Promotion Probes May Focus On Companies’ R&D Plans

Executive Summary

While federal prosecutors investigating allegations of "off-label" drug promotions focus on sales and marketing material, they also scrutinize a company's R&D plans

You may also be interested in...



Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads

FDA has unveiled the much-anticipated labeling change for GlaxoSmithKline's type 2 diabetes therapy Avandia, but is deeming the information about rosiglitzone's cardiovascular risk "inconclusive" and is asking the sponsor to undertake a long-term outcomes study to address outstanding safety questions

Off-Label Dissemination May Be Clarified – Indirectly – By FDAAA Regs

Issues surrounding off-label dissemination may be clarified through regulations required by the FDA Amendments Act of 2007

Bristol and DoJ finalize $500 million settlement

Bristol-Myers Squibb enters into a corporate integrity agreement with the Office of Inspector General as part of a settlement to resolve a variety of civil allegations Sept. 28. Bringing to end a lengthy investigation into Bristol's pricing, sales and marketing practices, the firm and Department of Justice finalize a settlement of $499 million; as anticipated, Bristol will pay over $317 million to the federal government and over $181 million to Medicaid-participating states with previously reserved funds (1"The Pink Sheet" Jan. 1, 2007, p. 13). DoJ alleges that Bristol: illegally paid health care providers to encourage them to purchase Bristol's products; knowingly promoted "off-label" uses of the atypical antipsychotic Abilify (aripiprazole); helped set fraudulent inflated prices; and knowingly misreported its best price for the antidepressant Serzone (nefazodone)...

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel